Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A

Summary

Turoctocog alfa pegol (N8-GP, Novo Nordisk, Bagsværd, Denmark), an extended half-life glycoPEGylated recombinant factor VIII (rFVIII), is being developed for prophylaxis and treatment of bleeds in haemophilia A patients. pathfinder^™5 is a multinational, open-label, single-arm trial to assess safety, efficacy and pharmacokinetics of N8-GP in paediatric (<12 years), previously treated patients. Boys with severe haemophilia A (<1 % FVIII), no history of inhibitors and previously treated with FVIII products (>50 exposure days [ED] for patients aged 0–5 years [younger cohort]; >150 ED for patients aged 6–11 years [older cohort]) were included. For prophylaxis, N8-GP was dosed at 50–75 IU/kg twice weekly; bleeds were treated with 20–75 IU/kg. Half-life was estimated for the patients’ previous FVIII product and for N8-GP. Sixty-eight patients received N8-GP; none developed inhibitors and no other concerns were identified. Median annualised bleeding rate was 1.95 (1.94 and 1.97 in the younger and older cohorts, respectively). Twenty-nine patients (42.6 %; 15 younger and 14 older children, respectively) did not report any bleeding while on N8-GP prophylaxis; 39 patients (57.4 %; 19 younger and 20 older children, respectively) reported 70 bleeds (all mild/moderate). N8-GP treatment was successful for 78.6 % of bleeds in all patients, 80.0 % in younger and 77.5 % in older patients. Most bleeds (80.0 %) were treated with ≤2 injections. Half-life ratio between N8-GP and the patients’ previous FVIII product was 1.85. N8-GP was well tolerated and provided effective prophylaxis and treatment of bleeds in paediatric patients with severe haemophilia A.

Trial registered at www.clinicaltrials.gov (NCT01731600).

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

GlycoPEGylated - haemophilia A - paediatrics - phase III - recombinant FVIII

• References

• 1 Srivastava A, Brewer AK, Mauser-Bunschoten EP. et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
• 2 Manco-Johnson MJ, Abshire TC, Shapiro AD. et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-544.
• 3 Tiede A. Half-life extended factor VIII for the treatment of hemophilia A. J Thromb Haemost 2015; 13 (Suppl. 01) S176-S179.
• 4 Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379: 1447-1456.
• 5 Fogarty PF. Biological rationale for new drugs in the bleeding disorders pipeline. Hematology Am Soc Hematol Educ Program 2011; 2011: 397-404.
• 6 Journeycake JM, Quinn CT, Miller KL. et al. Catheter-related deep venous thrombosis in children with hemophilia. Blood 2001; 98: 1727-1731.
• 7 Schulte S. Pioneering designs for recombinant coagulation factors. Thromb Res 2011; 128 (Suppl. 01) S9-12.
• 8 Ivens IA, Baumann A, McDonald TA. et al. PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers. Haemophilia 2013; 19: 11-20.
• 9 Carcao M. Changing paradigm of prophylaxis with longer acting factor concentrates. Haemophilia 2014; 20 (Suppl. 04) 99-105.
• 10 Coppola A, Di Capua M, Di Minno MN. et al. Treatment of hemophilia: a review of current advances and ongoing issues. J Blood Med 2010; 1: 183-195.
• 11 Tiede A, Brand B, Fischer R. et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11: 670-678.
• 12 Thim L, Vandahl B, Karlsson J. et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 2010; 16: 349-359.
• 13 Stennicke HR, Kjalke M, Karpf DM. et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 2013; 121: 2108-2116.
• 14 Giangrande P, Andreeva T, Chowdary P. et al. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. Thromb Haemost 2017; 117: 252-261.
• 15 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Tripartite harmonised guideline: Good Clinical Practice: Consolidated Guideline (E6). Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf/E6_R1_Guideline.pdf Accessed January 31, 2017
• 16 World Medical Association. Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. Available at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-researchinvolving-human-subjects/.cal-research-involving-human-subjects/ Accessed January 31 2017
• 17 Giles AR, Verbruggen B, Rivard GE. et al. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis. Thromb Haemost 1998; 79: 872-875.
• 18 European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109692.pdf Accessed December 7, 2015
• 19 European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf Accessed January 31, 2017
• 20 Shankar G, Shores E, Wagner C. et al. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 2006; 24: 274-280.
• 21 Santagostino E, Saxena K, Kenet G. et al. PROTECT FVIII Kids trial results: BAY 94–9027 safety and efficacy in previously treated children with severe hemophilia A. Haemophilia 2016; 22: 41.
• 22 Young G, Mahlangu J, Kulkarni R. et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost 2015; 13: 967-977.
• 23 Yang Q, Lai SK. Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2015; 7: 655-677.
• 24 Webster R, Didier E, Harris P. et al. PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies. Drug Metab Dispos 2007; 35: 9-16.
• 25 Baxalta. Baxalta’s ADYNOVATE meets endpoints in Phase 3 study of hemophilia A patients under 12 years of age. Available at: http://newsroom.baxalta.com/pressreleases/press-release-details/2015/Baxaltas-ADYNOVATE-Meets-Endpoints-in-Phase-3-Study-of-Hemophilia-A-Patients-Under-12-Years-of-Age/default.aspx Accessed January 31 2017
• 26 Auerswald G, Salek SZ, Benson G. et al. Beyond patient benefit: clinical development in hemophilia. Hematology 2012; 17: 1-8.